Dr. Daniel Weiner Will Discuss Challenges and Opportunities to Realize
Critical Path Initiative Goals
MOUNTAIN VIEW, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Daniel Weiner, Ph.D., senior vice president and chief technology officer, has been invited to speak to U.S. and Japanese biopharmaceutical executives attending a session on research and development productivity hosted by the New York Pharma Forum (NYPF), to be held in New York City, October 15, 2007.
Dr. Weiner's presentation will discuss the technical, organizational and process changes needed to reach the goals of the FDA's Critical Path Initiative for improving drug development productivity, including opportunities for the adoption of quantitative drug-disease modeling and simulation. Dr. Weiner will join other industry experts as part of the NYPF program entitled "R&D Productivity: Are There Winning Strategies?" The session will also offer a forum for interdisciplinary discussion on areas of opportunity in the drug development and approval process.
"Pharsight has built a strong reputation for providing critical
solutions that increase productivity in the drug development industry,"
said Shawn O'Connor, president, chief executive officer, and chairman of
Pharsight. "Through our strategic consulting services and growing family of
software products, we have successfully collaborated with global drug
developers to incorporate modeling and simulation into their development
processes. These collaborations have yielded a number of success stories,
ranging from increased efficiencies and more confident decision-making to
better resource management. Pharsight is pleased to participate at this
NYPF event, and to offer its perspectives on opportunities, challenges and
|SOURCE Pharsight Corporation|
Copyright©2007 PR Newswire.
All rights reserved